[1]熊常州,韩坤余,刘宁,等.长链非编码RNA烟酰胺核苷酸转氢酶-反义RNA1在肺癌发生发展中的作用研究进展[J].新乡医学院学报,2024,(4):388-391.[doi:10.7683/xxyxyxb.2024.04.017]
　XIONG Changzhou,HAN Kunyu,LIU Ning,et al.Research progress on the role of long non-coding RNA nicotinamide nucleotide transhydrogenase-antisense RNA1 in the occurrence and development of lung cancer[J].Journal of Xinxiang Medical University,2024,(4):388-391.[doi:10.7683/xxyxyxb.2024.04.017]
点击复制

长链非编码RNA烟酰胺核苷酸转氢酶-反义RNA1在肺癌发生发展中的作用研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
期数:
2024年4
页码:
388-391
栏目:
综述
出版日期:
2024-04-05

文章信息/Info

Title:
Research progress on the role of long non-coding RNA nicotinamide nucleotide transhydrogenase-antisense RNA1 in the occurrence and development of lung cancer
作者:
熊常州1; 韩坤余2; 刘宁1; 马帅1; 牛华涛3
（1.成都中医药大学临床医学院，四川　成都　610075；2.云南中医药大学第一临床医学院，云南　昆明　650021；3.云南省肿瘤医院神经外科，云南　昆明　650118）
Author(s):
XIONG Changzhou1; HAN Kunyu2; LIU Ning1; MA Shuai1; NIU Huatao3
(1.Clinical Medical College,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,Sichuan Province,China;2.The First Clinical Medical College,Yunnan University of Chinese Medicine,Kunming 650021,Yunnan Province,China;3.Department of Neurosurgery,Yunnan Cancer Hospital,Kunming 650118,Yunnan Province,China)
关键词:
肺癌; 长链非编码RNA烟酰胺核苷酸转氢酶-反义RNA1; 增殖; 耐药性
Keywords:
lung cancer; long non-coding RNA nicotinamide nucleotide transhydrogenase-antisense RNA1; proliferation; drug resistance
分类号:
R734.2
DOI:
10.7683/xxyxyxb.2024.04.017
文献标志码:
A
摘要:
肺癌是世界上致死率最高的恶性肿瘤，其主要治疗手段为外科手术、化学治疗、放射治疗、靶向治疗等。烟酰胺核苷酸转氢酶-反义RNA1(NNT-AS1)作为新发现的长链非编码RNA(lncRNA)分子，通过miR-3666/E2F2、miR-22-3p/YAP1、miR-22/FOXM1、miR-1236-3p/ATG7、miR-129-5p、丝裂原活化蛋白激酶/Slug等信号通路，与肺癌细胞的凋亡、增殖、迁移、侵袭有关，还参与介导肺癌细胞的顺铂耐药性，与肺癌的不良生存结局和较差的临床病理特征显著相关，可以为肺癌提供新的治疗靶点及预后标志物。本文就lncRNA NNT-AS1在肺癌发生发展中的作用研究进展进行综述。
Abstract:
Lung cancer is the malignant tumor with the highest fatality rate in the world,and its main treatment methods are surgery,chemotherapy,radiotherapy,and targeted therapy.Recent studies have found that nicotinamide nucleotide transhydrogenase-antisense RNA1 (NNT Antisense RNA 1,NNT-AS1),as a newly discovered long non-coding RNA (LncRNA) molecule,is correlated with the apoptosis,proliferation,migration and invasion of lung cancer tissues and cells through miR-3666/E2F2,miR-22-3p/YAP1,miR-22/FOXM1,miR-1236-3p/ATG7,miR-129-5p,Mitogen-activated protein kinase/Slug and other signaling pathways,and is also involved in the mediation of cisplatin resistance in lung cancer.NNT-AS1 is significantly associated with poor survival outcomes and poor clinicopathological characteristics of lung cancer,which can provide new therapeutic targets and prognostic markers for lung cancer.This article reviews the research progress on the role of LncRNA NNT-AS1 in the occurrence and development of lung cancer.

参考文献/References:

［1］　国家卫生健康委办公厅.原发性肺癌诊疗指南(2022年版)［J］.协和医学杂志,2022,13(4):549-570.
GENERAL OFFICE OF NATIONAL HEALTH COMMISSION OF THE PEOPLE′S REPUBLIC OF CHINA.Clinical practice guideline for primary lung cancer(2022 version)［J］.Med J Peking Union Med Coll Hosp,2022,13(4):549-570.
［2］　SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［3］　CHEN W,ZHENG R,BAADE P D,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［4］　BATISTA P J,CHANG H Y.Long noncoding RNAs:cellular address codes in development and disease［J］.Cell,2013,152(6):1298-1307.
［5］　RINN J L,CHANG H Y.Genome regulation by long noncoding RNAs［J］.Annu Rev Biochem,2012,81:145-166.
［6］　YANG J X,RASTETTER R H,WILHELM D.Non-coding RNAs:an introduction［J］.Adv Exp Med Biol,2016,886:13-32.
［7］　CHEN R,ZHANG C,CHENG Y,et al.LncRNA UCC promotes epi-thelial-mesenchymal transition via the miR-143-3p/SOX5 axis in non-small-cell lung cancer［J］.Lab Invest,2021,101(9):1153-1165.
［8］　HE W,ZHANG Y,XIA S.LncRNA NNT-AS1 promotes non-small cell lung cancer progression through regulating miR-22-3p/YAP1 axis［J］.Thorac Cancer,2020,11(3):549-560.
［9］　WANG H,GUO M,DING D,et al.Long non-coding RNA NNT-AS1 contributes to cisplatin resistance viamiR-1236-3p/ATG7 axis in lung cancer cells［J］.Onco Targets Ther,2020,13:3641-3652.
［10］　DERRIEN T,JOHNSON R,BUSSOTTI G,et al.The GENCODE 〖HJ1.76mm〗v7 catalog of human long noncoding RNAs:analysis of their gene structure,evolution,and expression［J］.Genome Res,2012,22(9):1775-1789.
［11］　KOPP F,MENDELL J T.Functional classification and experimental dissection of long noncoding RNAs［J］.Cell,2018,172(3):393-407.
［12］　BHAN A,SOLEIMANI M,MANDAL S S.Long noncoding RNA and cancer:a new paradigm［J］.Cancer Res,2017,77(15):3965-3981.
［13］　MA J,QI G,LI L.LncRNA NNT-AS1 promotes lung squamous cell carcinoma progression by regulating the miR-22/FOXM1 axis［J］.Cell Mol Biol Lett,2020,25:34.
［14］　SHEN Q,JIANG Y.LncRNA NNT-AS1 promotes the proliferation,and invasion of lung cancer cells via regulating miR-129-5p expression［J］.Biomed Pharmacother,2018,105:176-181.
［15］　WANG Q,YANG L,HU X,et al.Upregulated NNT-AS1,a long noncoding RNA,contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo［J］.Oncotarget,2017,8(2):3441-3453.
［16］　CHEN B,ZHAO Q,GUAN L,et al.Long non-coding RNA NNT-AS1 sponges miR-424/E2F1 to promote the tumorigenesis and cell cycle progression of gastric cancer［J］.J Cell Mol Med,2018,22(10):4751-4759.
［17］　LU Y B,JIANG Q,YANG M Y,et al.Long noncoding RNA NNT-AS1 promotes hepatocellular carcinoma progression and metastasis through miR-363/CDK6 axis［J］.Oncotarget,2017,8(51):88804-88814.
［18］　HUANG L,JIANG X,KANG P,et al.Long non-coding RNA NNT-AS1 functions as an oncogenic gene through modulating miR-485/BCL9 in cholangiocarcinoma［J］.Cancer Manag Res,2019,11:7739-7749.
［19］　ZHANG C,REN X,LIU Z,et al.Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers［J］.BMC Cancer,2020,20(1):879.
［20］　郭鹏,董栋栋,王进,等.转录因子在上皮间质转化中分子机制研究进展［J］.临床与病理杂志,2015,35(3):479-483.
GUO P,DONG D D,WANG J,et al.Recent progress of research on molecular mechanism of transcription factors in epithelial mesenchymal transition［J］.J Clin Pathol Res,2015,35(3):479-483.
［21］　PEINADO H,OLMEDA D,CANO A.Snail,Zeb and bHLH factors in tumour progression:an alliance against the epithelial phenotype［J］.Nat Rev Cancer,2007,7(6):415-428.
［22］　ZHANG J,TIAN X J,ZHANG H,et al.TGF-β-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops［J］.Sci Signal,2014,7(345):ra91.
［23］　陈晓,魏宇轩,魏立.长链非编码RNA NNT-AS1促进人肺癌细胞增殖并抑制细胞凋亡的研究［J］.医药论坛杂志,2019,40(1):4-8.
CHEN X,WEI Y X,WEI L.Study on long non-coding RNA NNT-AS1 promotes cell proliferation and inhibits cell apoptosis in human lung cancer［J］.J Med Forum,2019,40(1):4-8.
［24］　ZANCONATO F,CORDENONSI M,PICCOLO S.YAP/TAZ at the roots of cancer［J］.Cancer Cell,2016,29(6):783-803.
［25］　〖ZK(#〗ZHANG M Y,LIN J,KUI Y C.MicroRNA-345 suppresses cell invasion and migration in non-small cell lung cancer by directly targeting YAP1［J］.Eur Rev Med Pharmacol Sci,2019,23(6):2436-2443.
［26］　PU X,WANG J,LI W,et al.COPB2 promotes cell proliferation and tumorigenesis through up-regulating YAP1 expression in lung adenocarcinoma cells［J］.Biomedecine Pharmacother,2018,103:373-380.
［27］　HUANG J W,LUO X Y,LI Z H,et al.LncRNA NNT-AS1 regulates the progression of lung cancer through the NNT-AS1/miR-3666/E2F2 axis［J］.Eur Rev Med Pharmacol Sci,2020,24(1):238-248.
［28］　CAI Y,DONG Z Y,WANG J Y.LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway［J］.Eur Rev Med Pharmacol Sci,2018,22(15):4879-4887.
［29］　FANG C,WANG L,GONG C,et al.Long non-coding RNAs:how to regulate the metastasis of non-small-cell lung cancer［J］.J Cell Mol Med,2020,24(6):3282-3291.
［30］　SOSA IGLESIAS V,GIURANNO L,DUBOIS L J,et al.Drug resistance in non-small cell lung cancer:a potential for NOTCH targeting?［J］.Front Oncol,2018,8:267.
［31］　WANG P,CHEN D,MA H,et al.LncRNA SNHG12 contributes to multidrug resistance through activating the MAPK/Slug pathway by sponging miR-181a in non-small cell lung cancer［J］.Oncotarget,2017,8(48):84086-84101.
［32］　BUCHEGGER K,SILVA R,LPEZ J,et al.The ERK/MAPK pathway is overexpressed and activated in gallbladder cancer［J］.Pathol Res Pract,2017,213(5):476-482.
［33］　ASSANI G,ZHOU Y.Effect of modulation of epithelial-mesenchymal transition regulators Snail1 and Snail2 on cancer cell radio-sensitivity by targeting of the cell cycle,cell apoptosis and cell migration/invasion［J］.Oncol Lett,2019,17(1):23-30.
［34］　〖WB〗徐沙沙,项锋钢,党受琴,等.NF-κB与Slug在非小细胞肺癌及其上皮间质转化中的作用［J］.现代生物医学进展,2012,12(17):3232-3238.
〖DW〗XU S S,XIANG F G,DANG S Q,et al.The expression of NF-κB and slug in NSCLC and the effect on EMT［J］.Prog Mod Biomed,2012,12(17):3232-3238.
〖ZK）〗〖JY〗〖HT5”SS〗（

相似文献/References:

[1]杜华贞,和瑞芝,千高峰,等.肺癌痰液脱落细胞学检查——附164例分析[J].新乡医学院学报,1988,5(02):022.
[2]张彩平,范迎胜,李 新,等.肺癌患者医院真菌感染原因调查分析[J].新乡医学院学报,2002,19(05):416.
[3]朱自德.青年肺癌1O例临床分析[J].新乡医学院学报,2003,20(03):213.
[4]朱自德.青年肺癌10例临床分析[J].新乡医学院学报,2003,20(03):213.
[5]房秀清,尹丽欣,钞丽红.胸腔积液中癌胚抗原及CA125 和CA153 联合检测对肺癌的诊断意义[J].新乡医学院学报,2012,29(06):428.
[6]牛慧彦,王鑫,张萌,等.雷帕霉素联合多西紫杉醇对肺癌细胞增殖和凋亡的影响[J].新乡医学院学报,2012,29(01):000.
[7]孙 冰,杨亚勤,韩 伟,等.自发荧光支气管镜在肺癌早期诊断中的应用[J].新乡医学院学报,2013,30(03):223.
[8]郭煜颍,张　敏,刘彦廷,等.小分子酪氨酸激酶抑制剂安罗替尼在肺癌治疗中的应用研究进展[J].新乡医学院学报,2021,38(10):986.[doi:10.7683/xxyxyxb.2021.10.018]
[9]屈亚云,武莉芳,张秀敏,等.依达拉奉对肺癌胸腔镜手术中单肺通气相关肺损伤的保护作用[J].新乡医学院学报,2016,33(12):1054.[doi:10.7683/xxyxyxb.2016.12.010]
　QU Ya-yun,WU Li-fang,ZHANG Xiu-min,et al.Protective effect of edaravone on injury of lungs induced by one lung ventilation in lung cancer patients undergoing thorascopic surgery[J].Journal of Xinxiang Medical University,2016,33(4):1054.[doi:10.7683/xxyxyxb.2016.12.010]
[10]周　威,陈贡斌,刘海燕,等.黄芪甲苷对乌拉坦诱导肺癌小鼠的防治作用及其机制[J].新乡医学院学报,2021,38(1):018.[doi:10.7683/xxyxyxb.2021.01.004]
　ZHOU Wei,CHEN Gongbin,LIU Haiyan,et al.Preventive and therapeutic effects of astragaloside IV on urethane induced lung cancer in mice and its mechanism[J].Journal of Xinxiang Medical University,2021,38(4):018.[doi:10.7683/xxyxyxb.2021.01.004]

更新日期/Last Update: 2024-04-05